Vita Spring provided the funding as QuantuMDx also pursues commercialisation discussions with Sansure Biotech.
"I am very pleased to announce this equity investment today which will enable us to further evolve the Q-POC™ platform, making our system one of the most innovative, high multiplexing, molecular point of care devices in the market. Vita Spring shares our mission of developing accurate and efficient solutions to identify pathogens and diagnose diseases and so we are delighted they have chosen to invest in QuantuMDx. We are also looking forward to our close future relationship with Sansure and believe they will be an excellent partner for QuantuMDx in China as we look to increase our global footprint in Chinese and adjacent markets."
— Jonathan O’Halloran, Co-founder and Chief Executive
The round was backed by Chasnay Capital Partners alongside existing investors, retail investors, and Innovate UK.
"My north star is who I work with, and the level of enthusiasm, passion and desire to do great things at SleepCogni is outstanding. SleepCogni is a great example of hardware and software working together to have a truly life changing impact on patients."
The investment round was led by BGF with participation from Parkwalk and Sussex Place Ventures.
"Our approach at Entia is to empower patients with greater freedom whilst also equipping healthcare professionals with the insights to make more informed and personalised clinical decisions."
